118 related articles for article (PubMed ID: 21330048)
1. Intraprostatic injection therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.
Chapple C
Eur Urol; 2011 May; 59(5):755-6. PubMed ID: 21330048
[No Abstract] [Full Text] [Related]
2. Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Denmeade SR; Egerdie B; Steinhoff G; Merchant R; Abi-Habib R; Pommerville P
Eur Urol; 2011 May; 59(5):747-54. PubMed ID: 21129846
[TBL] [Abstract][Full Text] [Related]
3. Re: Samuel R. Denmeade, Blair Egerdie, Gary Steinhoff, et al. Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2011;59:747-54.
Cai T; Paolo DP; Malossini G
Eur Urol; 2011 Jun; 59(6):e33. PubMed ID: 21398021
[No Abstract] [Full Text] [Related]
4. Intraprostatic injectables for male lower urinary tract symptoms: Reality or fiction?
Alcántara Montero A; Pascual Regueiro N
Actas Urol Esp (Engl Ed); 2018 Jun; 42(5):350-351. PubMed ID: 29398093
[No Abstract] [Full Text] [Related]
5. [Intraprostatic injection therapy in patients with benign prostatic syndrome].
Bschleipfer T; Bach T; Gratzke C; Madersbacher S; Oelke M
Urologe A; 2013 Mar; 52(3):354-8. PubMed ID: 23435646
[TBL] [Abstract][Full Text] [Related]
6. Botulinum neurotoxin A for male lower urinary tract symptoms.
Chartier-Kastler E; Mehnert U; Denys P; Giuliano F
Curr Opin Urol; 2011 Jan; 21(1):13-21. PubMed ID: 21099691
[TBL] [Abstract][Full Text] [Related]
7. A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to 25 mg thrice daily.
Tsuritani S; Nozaki T; Okumura A; Kimura H; Kazama T
Urol Int; 2010; 85(1):80-7. PubMed ID: 20516676
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of tamsulosin hydrochloride and its mechanism in improving nocturia associated with lower urinary tract symptoms/benign prostatic hyperplasia.
Yoshida M; Inadome A; Masunaga K; Nagata T; Yoshiyasu T
Neurourol Urodyn; 2010 Sep; 29(7):1276-81. PubMed ID: 20878997
[TBL] [Abstract][Full Text] [Related]
9. Re: Nakai H, Yamanishi T, Yasuda K, Kitahara S, Suzuki T. 2004. Correlation between lower urinary tract symptoms and urethral function in benign prostatic hyperplasia.
Schaefer W
Neurourol Urodyn; 2006; 25(1):99-100. PubMed ID: 16178001
[No Abstract] [Full Text] [Related]
10. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
11. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847
[TBL] [Abstract][Full Text] [Related]
12. Change in urinary symptoms and quality of life in men with benign prostatic hyperplasia after transurethral resection of prostate.
Chalise PR; Agrawal CS
Nepal Med Coll J; 2007 Dec; 9(4):255-8. PubMed ID: 18298015
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
Antunes AA; Srougi M; Coelho RF; de Campos Freire G
Nat Clin Pract Urol; 2007 Mar; 4(3):155-60. PubMed ID: 17347660
[TBL] [Abstract][Full Text] [Related]
14. [New developments in the diagnosis of benign prostatic hyperplasia].
Vaida M; Novac B; Gheorghiu V; Novac C
Rev Med Chir Soc Med Nat Iasi; 2006; 110(1):88-96. PubMed ID: 19292085
[TBL] [Abstract][Full Text] [Related]
15. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years.
Te AE; Malloy TR; Stein BS; Ulchaker JC; Nseyo UO; Hai MA
BJU Int; 2006 Jun; 97(6):1229-33. PubMed ID: 16686717
[TBL] [Abstract][Full Text] [Related]
16. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
[TBL] [Abstract][Full Text] [Related]
17. Injectables in the prostate.
Saemi AM; Plante MK
Curr Opin Urol; 2008 Jan; 18(1):28-33. PubMed ID: 18090486
[TBL] [Abstract][Full Text] [Related]
18. Commentary on tolterodine for men with benign prostatic hyperplasia and lower urinary tract symptoms.
O'Leary MP
J Urol; 2008 May; 179(5 Suppl):S86. PubMed ID: 18405764
[No Abstract] [Full Text] [Related]
19. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A;
Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
[TBL] [Abstract][Full Text] [Related]
20. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.
Roehrborn CG
Int J Impot Res; 2008 Dec; 20 Suppl 3():S19-26. PubMed ID: 19002120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
